Full Press Release Details
| September 5, 2023
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
Read More
VANI Positive Sentiment
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
Key Takeaway: Vivani Medical's subsidiary, Cortigent, is set to present results from the Orion Clinical Study at The Eye and The Chip World Research Congress on Artificial Vision, taking place from October 8-10. This presentation highlights the potential advancements in artificial vision technology. The event is significant for stakeholders in the field of vision restoration.
Price reaction · baseline $0.93 (2023-09-01 close) · hit pre-market · 1 other VANI headline(s) in the window, move may be shared
day 0 close
+4.3%
day 1
+2.1%
day 3
+3.2%
Market Sentiment Analysis
POSITIVE FACTORS
- Cortigent will present promising results from the Orion Clinical Study.
- The presentation is at a significant event focused on artificial vision.
- The study's findings could contribute to advancements in vision restoration.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~10 mo
Medium dilution risk
Lead asset
Semaglutide
Phase 1 · Obesity & Overweight
Frequently Asked Questions
What is the Orion Clinical Study?
The Orion Clinical Study focuses on advancements in artificial vision technology.
When will the presentation take place?
The presentation will occur from October 8-10 at the Eye and Chip Congress.
Who is presenting the study results?
Cortigent, a subsidiary of Vivani Medical, will present the study results.
What is the significance of the Eye and Chip Congress?
The congress is a key event for stakeholders in the field of artificial vision.